文献速递肝肾功能剂量调整治疗药物监测与药物基因组学特殊人群用药

达托霉素的临床药代动力学特征

Clinical Pharmacokinetics of Daptomycin.
PubMed 文献 · Clin Pharmacokinet · 2020-12-14

本文综述达托霉素的药代动力学特征。达托霉素分布容积约0.1 L/kg,血浆蛋白结合率约90%,主要经肾排泄,约50%剂量以原形经尿排出,肾功能不全者需调整剂量。特定病理生理条件下药代动力学个体间变异大,重症监护、肾或肝功能不全、透析、肥胖或儿童患者可考虑进行治疗药物监测,临床疗效目标为AUC/MIC>666,残余浓度不应超过24.3 mg/L以限制肌肉不良反应风险。

要点

  • 达托霉素主要经肾排泄,约50%剂量以原形经尿排出,肾功能不全者需调整剂量。
  • 临床疗效目标为AUC/MIC>666,残余浓度不应超过24.3 mg/L以限制肌肉不良反应风险。
  • 重症监护、肾或肝功能不全、透析、肥胖或儿童患者可考虑进行治疗药物监测。

核心结论

  • 达托霉素的药代动力学在特定病理生理条件下发生改变,导致个体间变异大,特定患者可考虑进行治疗药物监测。

研究设计与样本

  • 本文为综述,系统汇总达托霉素的临床药代动力学特征。

主要发现

  • 达托霉素分布容积有限,健康志愿者中为0.1 L/kg,血浆蛋白结合率约90%。
  • 达托霉素消除主要经肾,约50%剂量以原形经尿排出。
  • 达托霉素的药代动力学在特定病理生理条件下发生改变,导致个体间变异大。

关键数值与推荐

  • 临床疗效目标为AUC/MIC>666。
  • 为限制肌肉不良反应风险,残余浓度不应超过24.3 mg/L。
  • 肾功能不全患者需调整剂量。

临床怎么用

  • 肾功能不全患者使用达托霉素需调整剂量。
  • 重症监护、肾或肝功能不全、透析、肥胖或儿童患者可考虑进行治疗药物监测。
  • 临床疗效目标为AUC/MIC>666,残余浓度不应超过24.3 mg/L以限制肌肉不良反应风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Due to the low level of resistance observed with daptomycin, this antibiotic has an important place in the treatment of severe Gram-positive infections. It is the first-in-class of the group of calcium-dependent, membrane-binding lipopeptides, and is a cyclic peptide constituted of 13 amino acids and an n-decanoyl fatty acid chain. The antibacterial action of daptomycin requires its complexation with calcium. Daptomycin is not absorbed from the gastrointestinal tract and needs to be administered parenterally. The distribution of daptomycin is limited (volume of distribution of 0.1 L/kg in healthy volunteers) due to its negative charge at physiological pH and its high binding to plasma proteins (about 90%). Its elimination is mainly renal, with about 50% of the dose excreted unchanged in the urine, justifying dosage adjustment for patients with renal insufficiency. The pharmacokinetics of daptomycin are altered under certain pathophysiological conditions, resulting in high interindividual variability. As a result, therapeutic drug monitoring of daptomycin may be of interest for certain patients, such as intensive care unit patients, patients with renal or hepatic insufficiency, dialysis patients, obese patients, or children. A target for the ratio of the area under the curve to the minimum inhibitory concentration > 666 is usually recommended for clinical efficacy, whereas in order to limit the risk of undesirable muscular effects the residual concentration should not exceed 24.3 mg/L.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Gregoire N, Chauzy A, Buyck J, et al. Clinical Pharmacokinetics of Daptomycin. Clin Pharmacokinet. 2020. PMID: 33313994. doi:10.1007/s40262-020-00968-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。